About Beta-1,3-galactosyltransferase 9
Beta-1,3-galactosyltransferase 9 (B3GALT9) is a protein
from Homo sapiens identified by UniProt accession
A8MXE2, 369 residues long.
MolForge cross-references it against 0 known binders and
10 disease associations.
Target properties
| Protein name | Beta-1,3-galactosyltransferase 9 |
| UniProt accession | A8MXE2 |
| Gene | B3GALT9 |
| Organism | Homo sapiens |
| Length | 369 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (10)
Diseases linked to this target (Open Targets).
- sex hormone-binding globulin measurement · score 0.06
- protein measurement · score 0.05
- platelet count · score 0.05
- mean platelet volume · score 0.04
- tiredness measurement · score 0.04
- alkaline phosphatase measurement · score 0.03
- birth weight · score 0.03
- Immature Reticulocyte Fraction Measurement · score 0.02
- systolic blood pressure · score 0.02
- relapsing-remitting multiple sclerosis · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-A8MXE2-F1 | alphafold | PREDICTED | 88.14 | — |
Amino-acid sequence (369 residues)
MQVTFCRLRT HQWCFILFNV ILFHALLFGT DFVEEYFLHS LPYIDVKVLE IKNKARKLNI EPLRSNLSKY YVLSQSEICK GKNIFLLSLI FSSPGNGTRR DLIRKTWGNV TSVQGHPILT LFALGMPVSV TTQKEINKES CKNNDIIEGI FLDSSENQTL KIIAMIQWAV AFCPNALFIL KVDEETFVNL PSLVDYLLNL KEHLEDIYVG RVLHQVTPNR DPQNRDFVPL SEYPEKYYPD YCSGEAFIMS QDVARMMYVV FKEVPMMVPA DVFVGICAKF IGLIPIHSSR FSGKRHIRYN RCCYKFIFTS SEIADPEMPL AWKEINDGKE CTLFETSYEL ISCKLLTYLD SFKRFHMGTI KNNLMYFAD
Explore Beta-1,3-galactosyltransferase 9 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets